Lindbrook Capital’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Lindbrook Capital’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-941	Closed	-$1K	–	3061
2022 Q3	$1K	Sell	941 -115	-11%	-$261	﹤0.01%	2583
2022 Q2	$2K	Buy	+1,056	New	+$1.83K	﹤0.01%	2109
2022 Q1	–	Sell	-8,481	Closed	-$39K	–	2661
2021 Q4	$39K	Buy	8,481 +8,134	+2,344%	+$50.5K	0.01%	805
2021 Q3	$3K	Hold	347	–	–	﹤0.01%	1474
2021 Q2	$3K	Hold	347	–	–	﹤0.01%	1532
2021 Q1	$3K	Sell	347 -96	-22%	-$1.01K	﹤0.01%	1488
2020 Q4	$3K	Buy	443 +14	+3%	+$112	﹤0.01%	1396
2020 Q3	$5K	Sell	429 -62	-13%	-$567	﹤0.01%	1141
2020 Q2	$3K	Buy	491 +144	+41%	+$551	﹤0.01%	1324
2020 Q1	$1K	Buy	+347	New	+$999	﹤0.01%	1625

Other funds holding SRNE

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BRF

B. Riley Financial Los Angeles, California $434M AUM 751.56% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Rafferty Asset Management New York $43.9B AUM 121.74% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Lindbrook Capital's SRNE Position: Q4 2022 in Review

Lindbrook Capital sold out of Sorrento Therapeutics, Inc. (SRNE) in Q4 2022, closing a stake of 941 shares — an estimated $1K sold.

Lindbrook Capital first reported a position in SRNE in Q1 2020 and held it in 10 quarters. The position peaked at $39K in Q4 2021. 221 funds tracked by Wall St. Rank hold SRNE as of Q4 2022.

Lindbrook Capital reported no remaining Sorrento Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
Lindbrook Capital sold 941 Sorrento Therapeutics, Inc. shares in Q4 2022, an estimated $1K.
Lindbrook Capital first reported a position in Sorrento Therapeutics, Inc. in Q1 2020 and held it in 10 quarters.
Lindbrook Capital's Sorrento Therapeutics, Inc. position peaked at $39K in Q4 2021.
221 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2022.

Based on Lindbrook Capital's 13F filing for Q4 2022, filed 25 Jan 2023.